Genome-wide profiling of human papillomavirus DNA integration in liquid-based cytology specimens from a Gabonese female population using HPV capture technology.
Cytodiagnosis
/ methods
DNA, Viral
/ analysis
Female
Gabon
/ epidemiology
Genotype
High-Throughput Nucleotide Sequencing
/ methods
Humans
Incidence
Papillomaviridae
/ genetics
Papillomavirus Infections
/ complications
Sequence Analysis, DNA
/ methods
Uterine Cervical Neoplasms
/ epidemiology
Virus Integration
/ genetics
Uterine Cervical Dysplasia
/ epidemiology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 02 2019
06 02 2019
Historique:
received:
13
10
2017
accepted:
10
12
2018
entrez:
8
2
2019
pubmed:
8
2
2019
medline:
1
9
2020
Statut:
epublish
Résumé
Human papillomavirus (HPV) is recognised as the cause of precancerous and cancerous cervical lesions. Furthermore, in high-grade lesions, HPV is frequently integrated in the host cell genome and associated with the partial or complete loss of the E1 and E2 genes, which regulate the activity of viral oncoproteins E6 and E7. In this study, using a double-capture system followed by high-throughput sequencing, we determined the HPV integration status present in liquid-based cervical smears in an urban Gabonese population. The main inclusion criteria were based on cytological grade and the detection of the HPV16 genotype using molecular assays. The rate of HPV integration in the host genome varied with cytological grade: 85.7% (6/7), 71.4% (5/7), 66.7% (2/3) 60% (3/5) and 30.8% (4/13) for carcinomas, HSIL, ASCH, LSIL and ASCUS, respectively. For high cytological grades (carcinomas and HSIL), genotypes HPV16 and 18 represented 92.9% of the samples (13/14). The integrated form of HPV16 genotype was mainly found in high-grade lesions in 71.4% of samples regardless of cytological grade. Minority genotypes (HPV33, 51, 58 and 59) were found in LSIL samples, except HPV59, which was identified in one HSIL sample. Among all the HPV genotypes identified after double capture, 10 genotypes (HPV30, 35, 39, 44, 45, 53, 56, 59, 74 and 82) were detected only in episomal form. Our study revealed that the degree of HPV integration varies with cervical cytological grade. The integration event might be a potential clinical prognostic biomarker for the prediction of the progression of neoplastic lesions.
Identifiants
pubmed: 30728408
doi: 10.1038/s41598-018-37871-2
pii: 10.1038/s41598-018-37871-2
pmc: PMC6365579
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1504Références
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Cancer Res. 1999 Nov 1;59(21):5615-24
pubmed: 10554043
Cancer Res. 2000 Nov 1;60(21):5916-21
pubmed: 11085503
Int J Cancer. 2001 Apr 1;92(1):9-17
pubmed: 11279600
Int J Cancer. 2001 Oct 15;94(2):153-6
pubmed: 11668491
Virus Res. 2002 Nov;89(2):183-90
pubmed: 12445658
J Gen Virol. 1992 Aug;73 ( Pt 8):2059-66
pubmed: 1322962
J Gen Virol. 1992 Sep;73 ( Pt 9):2327-36
pubmed: 1328489
J Pathol. 2004 Jan;202(1):23-33
pubmed: 14694518
Cancer Res. 2004 Jun 1;64(11):3878-84
pubmed: 15172997
J Clin Pathol. 1991 Dec;44(12):990-6
pubmed: 1665153
J Clin Microbiol. 2006 May;44(5):1755-62
pubmed: 16672403
Med Oncol. 2011 Dec;28(4):1411-7
pubmed: 20467918
J Pathol. 2010 Jul;221(3):320-30
pubmed: 20527025
J Mol Diagn. 2011 May;13(3):325-33
pubmed: 21497292
Curr Opin Biotechnol. 2012 Feb;23(1):9-15
pubmed: 22154470
Lancet. 2012 Nov 24;380(9856):1840-50
pubmed: 23079588
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD008054
pubmed: 23543559
G3 (Bethesda). 2013 Aug 07;3(8):1213-24
pubmed: 23550136
Asian Pac J Cancer Prev. 2013;14(6):3837-41
pubmed: 23886192
Nature. 2013 Aug 8;500(7461):207-11
pubmed: 23925245
Int J Biol Markers. 2014 Mar 24;29(1):e78-85
pubmed: 24170557
Genome Res. 2014 Feb;24(2):185-99
pubmed: 24201445
Nature. 2014 Feb 20;506(7488):371-5
pubmed: 24390348
Int J Gynecol Cancer. 2014 Feb;24(2):329-38
pubmed: 24418928
Br J Cancer. 2014 Feb 18;110(4):1034-44
pubmed: 24423925
BMC Bioinformatics. 2014 Oct 22;15:348
pubmed: 25331652
Nat Genet. 2015 Feb;47(2):158-63
pubmed: 25581428
Int J Cancer. 2015 Aug 15;137(4):776-83
pubmed: 25626421
Br J Cancer. 2015 Jun 9;112(12):1958-65
pubmed: 25973533
Exp Ther Med. 2015 Dec;10(6):2169-2174
pubmed: 26668611
Nat Genet. 2016 Jan;48(1):2-4
pubmed: 26711106
Infect Agent Cancer. 2016 Jan 15;11:2
pubmed: 26779280
Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):1004-5
pubmed: 27009212
Infect Agent Cancer. 2016 Aug 16;11:42
pubmed: 27532014
Infect Agent Cancer. 2016 Sep 07;11(1):50
pubmed: 27610192
Sci Rep. 2016 Oct 19;6:35427
pubmed: 27759101
BMC Genomics. 2016 Nov 2;17(1):851
pubmed: 27806689
J Exp Clin Cancer Res. 2016 Nov 25;35(1):180
pubmed: 27884161
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
Virology. 1987 Nov;161(1):259-61
pubmed: 2823467
Open Med (Wars). 2014 Sep 25;10(1):1-7
pubmed: 28352670
Int J Mol Sci. 2017 Sep 22;18(10):null
pubmed: 28937589
NPJ Genom Med. 2016 Mar 16;1:16004
pubmed: 29263809
Int J Cancer. 1997 Feb 20;74(1):50-6
pubmed: 9036869